{"id":307452,"date":"2026-10-14T12:11:34","date_gmt":"2026-10-14T06:41:34","guid":{"rendered":"https:\/\/univest.in\/blogs-2\/?p=307452"},"modified":"2026-10-14T12:11:34","modified_gmt":"2026-10-14T06:41:34","slug":"branded-formulation-biologics-and-pharma-service-stocks-roadmap-leaders-roundup","status":"publish","type":"post","link":"https:\/\/univest.in\/blogs-2\/branded-formulation-biologics-and-pharma-service-stocks-roadmap-leaders-roundup\/","title":{"rendered":"3 Branded Formulation, Biologics and Pharma Service Stocks With a Strong Future Roadmap: Mankind Pharma, Shilpa Medicare and Indegene"},"content":{"rendered":"

Mankind Pharma Rs 2,372.00, P\/E 47.91. Shilpa Medicare Rs 973.60, P\/E 67.52. Indegene Rs 580.70, P\/E 35.20. Closing prices of 13 Oct 2026.<\/em><\/p>\n

\n

Quick Answer<\/strong><\/p>\n

Branded formulation, biologics and pharma service stocks with the clearest long-term roadmaps today include Mankind Pharma in branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Shilpa Medicare in active ingredients, formulations, biologics and contract manufacturing and Indegene in commercial, medical and regulatory services for life science companies. FY26 revenue growth was 14.8% at Mankind Pharma, 18.2% at Shilpa Medicare and 21.6% at Indegene. P\/E stands at 47.91 for Mankind Pharma (industry 37.59), 67.52 for Shilpa Medicare (industry 37.59) and 35.20 for Indegene (industry 62.79). Demand cycles, input costs and valuation decide how much of that growth the market keeps paying for, so each company’s risks need equal attention.<\/p>\n<\/p><\/div>\n

Branded formulation, biologics and pharma service stocks give investors exposure to medicines, advanced therapies and services that doctors and drug makers rely on. Prescription growth, contract orders and client wins decide how much of that demand turns into profit.<\/p>\n

This list covers three branded formulation, biologics and pharma service stocks: Mankind Pharma for branded formulations across chronic and acute therapies, a consumer healthcare arm and a large field force, Shilpa Medicare for active ingredients, formulations, biologics and contract manufacturing and Indegene for commercial, medical and regulatory services for life science companies. Every figure comes from the latest reported financials and the 13 October 2026 market close. Companies without complete current figures were left out.<\/p>\n

Click Here – Get Free Investment Predictions<\/strong><\/a><\/p>\n

\n
\n

Table of Contents<\/p>\nToggle<\/span><\/path><\/svg><\/svg><\/span><\/span><\/span><\/a><\/span><\/div>\n